Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADA | P00813 | 6/20 | 1.00 |
| ▸ | PDE2A | O00408 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | PDE4B | Q07343 | 1/20 | 1.00 |
| ▸ | PDE4C | Q08493 | 1/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 0.98 |
| ▸ | BLM | P54132 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ehna SCHEMBL1742893 | 1.00 | ADA (1.00) | ADAPDE2ACYP3A4PDE4APDE4B | |
| (+)-Ehna SCHEMBL1742728 | 1.00 | ADA (1.00) | ADAPDE2ACYP3A4PDE4APDE4B | |
| (+)-Ehna SCHEMBL14985129 | 1.00 | ADA (1.00) | ADAPDE2ACYP3A4PDE4APDE4B | |
| (+)-Ehna SCHEMBL29481903 | 0.99 | PDE2A (1.00) | ADAPDE2ACYP3A4PDE4APDE4B | |
| (+)-Ehna SCHEMBL14975587 | 0.99 | PDE2A (1.00) | ADAPDE2ACYP3A4PDE4APDE4B | |
| Ehna SCHEMBL29391683 | 0.99 | PDE2A (1.00) | ADAPDE2ACYP3A4PDE4APDE4B | |
| SCHEMBL1740514 | 0.99 | ADA (0.98) | ADAPDE2ACYP3A4PDE4APDE4B | |
| SCHEMBL9083113 | 0.90 | ADA (0.82) | ADAPDE2ACYP3A4PDE4APDE4B | |
| SCHEMBL9083109 | 0.90 | ADA (0.82) | ADAPDE2ACYP3A4PDE4APDE4B | |
| SCHEMBL8585722 | 0.90 | ADA (0.82) | ADAPDE2ACYP3A4PDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3713572-B1 | TREATMENT OF TACHYCARDIA | OSLO UNIV HOSPITAL HF (NO) | 2025-07-30 | — | — | EP | claimed |
| CN-120018870-A | Drug coated medical device and method of manufacture | 巴德血管外围设备公司 | 2025-05-16 | — | — | CN | claimed |
| US-12280057-B2 | Vasoactive topical compound to affect tissue blood flow, reduce tissue necrosis and promote healing | SOUTH DAKOTA BOARD OF REGENTS (US) | 2025-04-22 | — | — | US | claimed |
| WO-2025075499-A1 | REDUCING DOPAMINE FEED-BACK INHIBITION IN DOPAMINERGIC CELLS BY TADALAFIL. | UNIVERSITEIT VAN AMSTERDAM (NL) | 2025-04-10 | — | — | WO | claimed |
| WO-2024191445-A1 | THERAPEUTIC BIO-ABSORBABLE POLYMERIC SCAFFOLD WITH DRUG-LOADED MICRO-NEEDLES FOR DRUG DELIVERY | BECTON, DICKINSON AND COMPANY (US) | 2024-09-19 | — | — | WO | claimed |
| WO-2024168242-A1 | POINT-OF-CARE DEVICE FOR THE DETERMINATION OF ADENOSINE DEAMINASE ACTIVITY IN BIOLOGICAL SAMPLES | IN VITRO DIAGNOSTIC SOLUTIONS (US) | 2024-08-15 | — | — | WO | claimed |
| WO-2023012244-A1 | COMBINATION THERAPY | JAZ Innovation Limited (GB) | 2023-02-09 | — | — | WO | claimed |
| US-20220362251-A1 | TREATMENT OF TACHYCARDIA | OSLO UNIVERSITY HOSPITAL HF (NO) | 2022-11-17 | — | — | US | claimed |
| US-11419874-B2 | Treatment of tachycardia | OSLO UNIVERSITY HOSPITAL HF (NO) | 2022-08-23 | — | — | US | claimed |
| CN-111239303-B | Method for simultaneously determining concentrations of ticagrelor, active metabolites thereof and endogenous adenosine in human plasma by liquid chromatography-mass spectrometry | 上海长海医院 | 2022-07-22 | — | — | CN | claimed |
| EP-3979996-A1 | METHODS AND FORMULATIONS FOR TREATING VISION DISORDERS | Jenivision Inc. (US) | 2022-04-13 | — | — | EP | claimed |
| CN-113993511-A | Methods and formulations for treating visual disorders | 杰尼视界公司 | 2022-01-28 | — | — | CN | claimed |
| CN-104725628-B | A kind of single functionalization branched polyethylene glycol, preparation method and its bio-related substance containing degradable group | 厦门赛诺邦格生物科技股份有限公司 | 2018-04-17 | — | — | CN | claimed |
| US-20120202287-A1 | Stem Cell Culture Methods | ITI SCOTLAND LIMITED (GB) | 2012-08-09 | — | — | US | claimed |
| EP-2389436-A2 | STEM CELL CULTURE METHODS | ITI Scotland Limited (GB) | 2011-11-30 | — | — | EP | claimed |
| US-20110257911-A1 | SYSTEMS AND METHODS FOR DETECTING CHANGES IN ENERGY USAGE IN A BUILDING | JOHNSON CONTROLS TECHNOLOGY COMPANY | 2011-10-20 | — | — | US | claimed |
| WO-2010084300-A2 | STEM CELL CULTURE METHODS | ITI SCOTLAND LIMITED (GB) | 2010-07-29 | — | — | WO | claimed |
| US-7507707-B2 | Methods of inducing ovulation using a non-polypeptide camp level modulator | LABORATOIRES SERONO SA (CH) | 2009-03-24 | — | — | US | claimed |
| EP-4676556-A1 | RADIATION SPACER HYDROGELS, METHODS OF FORMING, AND METHODS OF USE | Clearstream Technologies Limited (IE) | 2026-01-14 | — | — | EP | disclosed |
| EP-0227844-A1 | ANTIVIRAL DRUG | TEIJIN LIMITED (JP) | 1987-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11419874-B2 | Treatment of tachycardia | PDE4B, PDE2A, PDE5A | ADA 2521/4885PDE2A 2/4885CYP3A4 566/4885 |
| US-20220362251-A1 | TREATMENT OF TACHYCARDIA | PDE12, PDE2A, PDE4B | ADA 2259/4885PDE2A 2/4885CYP3A4 570/4885 |
| US-20120202287-A1 | Stem Cell Culture Methods | KIT, SOX18, MCL1 | ADA 4438/4885PDE2A 3669/4885CYP3A4 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.